Artificial intelligence (AI) has been the word of 2023, but aside from the promises, what are the realities of its practical implementation in the life sciences setting?
Roche has broken new ground with its ALK inhibitor Alecenesa, becoming the first drug in the class to be approved by the FDA for adjuvant use after surgery in early-stage,
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
